
    
      The study consists of a Base Stage wherein Chinese girls aged 9-19 years and young women aged
      20-26 years receive a 3-dose regimen of V501 and are followed up to 1 month postdose 3 (Month
      7). Participants aged 9-19 years who received 3 doses of V501 in the Base Stage will be
      eligible to participate in the Extension Stage and will be followed up to Month 60. No study
      vaccine will be administered during the Extension Stage.
    
  